The convergence of biology, cloud computing, artificial intelligence, and laboratory automation is creating a new attack surface that is drawing attention from CISOs, security teams, and risk managers. This emerging discipline is known as Cyberbiosecurity and focuses on protecting the digital infrastructure that supports scientific research, genetic data, laboratory operations, and biotechnology environments.
For years, cybersecurity efforts focused primarily on networks, applications, endpoints, and cloud environments. Today, pharmaceutical companies, biotech firms, research laboratories, and healthcare organizations operate highly digitalized ecosystems where cyber incidents can affect scientific outcomes, intellectual property, and sensitive operational processes.
When attackers target more than data
In Red Team engagements, it is increasingly common to encounter laboratory systems, sample management platforms, genetic sequencing environments, and scientific applications with weaker security controls than traditional enterprise infrastructure.
The risk extends beyond data theft. An attacker with privileged access could alter records, manipulate operational parameters, compromise data processing pipelines, or introduce inconsistencies capable of affecting research outcomes long before detection.
This becomes particularly relevant in environments that rely on laboratory automation, third-party APIs, scientific SaaS platforms, and AI-driven biomedical analysis.
Intellectual property has become a strategic target
The financial value associated with pharmaceutical, biotech, and genomic research has made the sector attractive for cyber espionage. Proprietary formulas, manufacturing processes, AI models, clinical studies, and research results can represent billions of dollars in competitive value.
From an offensive security perspective, the attack paths remain familiar: compromised credentials, vulnerable web applications, cloud misconfigurations, third-party suppliers, and insecure remote access.
The difference lies in the potential impact of the information being targeted.
A debate dividing experts
Not everyone agrees on the scale of Cyberbiosecurity risks.
Some experts argue that the increasing digitalization of biological systems requires proactive protection before major incidents occur. Others believe that certain scenarios remain largely speculative and that risks may sometimes be overstated to accelerate regulation, funding, or tighter control over biological information.
For security leaders, the key takeaway is straightforward: scientific and biological assets are now directly dependent on digital security.
The incident that raised awareness
The 2020 cyberattack against the European Medicines Agency highlighted the sector's exposure. Attackers gained unauthorized access to documents related to Pfizer and BioNTech COVID-19 vaccine submissions.
The incident reinforced a lesson frequently observed during offensive assessments: organizations may secure their own environments effectively while partners, suppliers, and regulatory entities remain viable attack paths.
Artificial intelligence expands the attack surface
The growing adoption of AI in biomedical research introduces additional security concerns. Models used for genetic analysis, drug discovery, and scientific data interpretation rely on highly sensitive datasets.
Data manipulation attacks, training pipeline compromise, dataset poisoning, and model exposure are becoming relevant considerations for organizations integrating AI into critical scientific workflows.
While many of these risks continue to evolve, they are already part of ongoing discussions among offensive security professionals, governance teams, and risk management programs.
What CISOs should focus on
- Map laboratory assets connected to corporate networks.
- Review privileged access controls.
- Perform penetration testing against scientific applications and research platforms.
- Assess supplier and third-party security exposure.
- Implement integrity monitoring for critical datasets.
- Include laboratory environments in vulnerability management programs.
- Conduct Red Team exercises simulating espionage and data manipulation scenarios.
Conclusion
Cyberbiosecurity is still an emerging discipline, and debates about the scale of future risks will likely continue.
What is already clear is that research institutions, pharmaceutical companies, biotech organizations, and laboratories are operating increasingly valuable and interconnected digital ecosystems.
For offensive security professionals, this represents a new attack surface. For CISOs and risk leaders, it highlights the need to determine whether scientific environments are receiving the same level of scrutiny as traditional enterprise infrastructure.
At Antisec, Red Team assessments, advanced penetration testing, DevSecOps programs, and vCISO services help organizations identify real-world exposure before adversaries do. When research, intellectual property, and critical data are involved, technical visibility becomes an operational requirement.
